Recent Patents on CNS Drug Discovery (Discontinued)

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078


Glutamatergic Dysfunction-Newer Targets for Anti-Obsessional Drugs

Author(s): Sagnik Bhattacharyya and Koushik Chakraborty

Affiliation: Section of Neuroimaging,Box 67, Division of Psychological Medicine, Institute of Psychiatry, King’s College London, De Crespigny Park, SE5 8AF, UK.


Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.

Keywords: Glutamate, serotonin, obsessive compulsive disorder, metabotropic glutamate receptor antagonist

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [47 - 55]
Pages: 9
DOI: 10.2174/157488907779561727